
Representative Marjorie Taylor Greene of Georgia has made headlines with her recent stock purchases, which include shares of Novo Nordisk A/S (NYSE:NVO). According to a filing disclosed on October 20, 2025, Greene invested between $1,001 and $15,000 in Novo Nordisk stock on October 15, 2025.
In addition to Novo Nordisk, Greene’s trading activities on the same day included purchasing shares of several other prominent companies. These transactions involved investments in Amazon.com (NASDAQ:AMZN), Adobe (NASDAQ:ADBE), Exelon (NASDAQ:EXC), the iShares Bitcoin Trust ETF (NASDAQ:IBIT), and Tesla (NASDAQ:TSLA), each within the same price range of $1,001 to $15,000.
Stock Performance and Recent Dividend
Shares of Novo Nordisk opened at $53.37 on the day of Greene’s purchase. The stock has fluctuated significantly over the past year, with a 52-week low of $45.05 and a high of $116.43. The company’s market capitalization stands at approximately $238.29 billion, with a price-to-earnings ratio of 14.66.
On August 6, 2025, Novo Nordisk reported quarterly earnings of $0.97 per share, surpassing analysts’ expectations of $0.93. The company generated revenue of $11.69 billion during this quarter, reflecting a robust performance. The firm also declared a semi-annual dividend of $0.4119, which was paid out on August 26, 2025. This dividend represented a yield of 240.0%, with a payout ratio of 22.53%.
Analyst Ratings and Institutional Investment Trends
Recent analyst ratings for Novo Nordisk indicate a mix of optimism and caution. Sanford C. Bernstein upgraded the stock from “market perform” to “outperform” in early September, while BNP Paribas Exane shifted its rating from “underperform” to “neutral” with a target price of $54.00. Conversely, Morgan Stanley downgraded the stock from “overweight” to “underweight,” lowering its price objective to $47.00.
Investment trends reveal that institutional investors have been actively adjusting their stakes in Novo Nordisk. Notable changes include Jennison Associates LLC increasing its shares by 0.3%, while Loomis Sayles & Co. L P raised its holdings by 1.5%. Kingstone Capital Partners Texas LLC significantly boosted its position with a dramatic increase of 301,443.6%, acquiring 10,005,216 shares valued at approximately $690.56 million.
As of now, two investment analysts have rated Novo Nordisk with a “Strong Buy,” while seven have assigned a “Buy” rating. Overall, there is a consensus rating of “Moderate Buy,” with an average target price of $76.00.
About Marjorie Taylor Greene and Novo Nordisk
Marjorie Taylor Greene has represented Georgia’s 14th Congressional District since January 3, 2021. She is currently running for re-election in the upcoming 2026 election. Her investment decisions, particularly in the pharmaceutical sector, reflect a growing trend among politicians to engage in stock trading, raising discussions about potential conflicts of interest.
Founded in 1923, Novo Nordisk A/S specializes in the research, development, and distribution of pharmaceutical products across various regions, including Europe, the Middle East, and North America. The company operates primarily in the fields of diabetes and obesity care, as well as rare diseases, positioning itself as a significant player in global health.
The recent trading activities of Representative Greene and the performance of Novo Nordisk underscore the interconnectedness of politics and market dynamics, inviting scrutiny into the implications of political figures investing in publicly traded companies.